Highlights the risk of potentially fatal myocarditis early in the course of clozapine treatment, emphasizing the need for early recognition.
Answers are grounded in this paper and cite their sources.
Supports early myocarditis monitoring after clozapine start; hypothesis-generating and should not yet change practice.
Clozapine is an atypical antipsychotic used for treatment resistant schizophrenia. Its potential to induce agranulocytosis is well known but it can also cause myocarditis. Clozapine is the only antipsychotic known to induce this side effect, typically early in the treatment, and literature is scarce on this condition. We are presenting a case report of a 21-year-old schizophrenic male who developed myocarditis within 3 weeks of starting on clozapine for his treatment resistant psychosis. We then aim to review some of the available literature and raise awareness among physicians as this condition can potentially be fatal if not detected early.
No takes yet. Share an insight, caveat, or question.
Munshi et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: